US2005239708A1PendingUtilityA1

Use of factor VIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis

Assignee: NOVO NORDISK HEALTHCARE AGPriority: Jul 14, 1999Filed: Jun 14, 2005Published: Oct 27, 2005

Est. expiryJul 14, 2019(expired)· nominal 20-yr term from priority

Inventors:Mirella Ezban Lars Christian Petersen Agneta Siegbahn

A61P 35/00A61P 35/04A61P 43/00A61P 9/10A61P 9/00A61P 17/02C12Y 304/21021C12N 9/6437A61K 38/00A61K 38/36

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to cell migration or treated by specific regulation of cell migration or chemotaxis.

Claims

exact text as granted — not AI-modified

1 . A method of treating burns in a patient comprising delivering FVIIa to the patient in an amount and under conditions suitable for treating burns.  
     
     
         2 . A method of treating inflammation in a patient comprising delivering FVIIa to the patient in an amount and under conditions suitable for treating inflammation.  
     
     
         3 . A method for inducing or enhancing the regeneration of vessel walls in a patient comprising delivering FVIIa to the patient in an amount and under conditions suitable for inducing or enhancing the regeneration of vessel walls.

Join the waitlist — get patent alerts

Track US2005239708A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.